Integrated genomic and proteomic analyses identify PYGL as a novel experimental therapeutic target for clear cell renal cell carcinoma

Integrated genomic and proteomic analyses identify PYGL as a novel experimental therapeutic target for clear cell renal cell carcinoma

Sunitinib, the first-line targeted therapy for metastatic clear cell renal cell carcinoma (ccRCC), faces a significant challenge as most patients develop acquired resistance. Integrated genomic and proteomic analyses identified PYGL as a novel therapeutic target for ccRCC. PYGL knockdown inhibited c...

Full description

Bibliographic Details
Main Authors: Mingyong Li, Guoqiang Zhu, Yiqi Liu, Xuefeng Li, Yuxia Zhou, Cheng Li, Minglei Wang, Jin Zhang, Zhenping Wang, Shuangfeng Tan, Wenqi Chen, Hu Zhang
Format: Article
Language:English
Published: Elsevier 2024-03-01
Series:Heliyon
Subjects:
ccRCC
PYGL
Target therapy
Sunitinib
Resistance
Online Access:http://www.sciencedirect.com/science/article/pii/S2405844024043263

Similar Items

Similar Items